Clinical Trials Logo

Coronary Microvascular Disease clinical trials

View clinical trials related to Coronary Microvascular Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06212466 Not yet recruiting - Myocardial Ischemia Clinical Trials

MCG as a Noninvasive Diagnostic Strategy for INOCA

MICRO2
Start date: February 26, 2024
Phase:
Study type: Observational

A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.

NCT ID: NCT05793567 Not yet recruiting - Clinical trials for Myocardial Infarction

A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)

Start date: November 2024
Phase:
Study type: Observational

The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).

NCT ID: NCT04220372 Not yet recruiting - Clinical trials for Coronary Microvascular Disease

Tongxinluo Capsule for Coronary Microvascular Disease

Start date: January 2020
Phase: Phase 4
Study type: Interventional

To investigate the efficacy and safety of Tongxinluo in patients with microvascular angina pectoris. Long-term follow-up of 1 to 5 years will be performed to evaluate the effect of Tongxinluo on long-term adverse cardiovascular events in patients with coronary microvascular disease.

NCT ID: NCT04218916 Not yet recruiting - Clinical trials for Coronary Microvascular Disease

Rhodiola Rosea for Coronary Microvascular Disease

Start date: January 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the effects of rhodiola rosea on coronary flow reserve and symptoms in patients with microvascular angina pectoris, and to evaluate adverse drug reactions. Long-term clinical follow-up of 1 to 3 years was conducted to evaluate the effect of rhodiola rosea on long-term adverse cardiovascular events in patients with coronary microvascular disease.